-- Additional Data Reveal that Higher Initial Doses of FOSRENOL Result in More Rapid Control of Mean Serum Phosphorus than Lower Initial Doses -- Chicago, IL (April 20, 2006)-According to data ...

Shire received a warning letter from the FDA’s Division of Drug Marketing, Advertising and Communications (DDMAC) asking the drugmaker to stop the distribution of specific professional marketing ...

Philadelphia, Pa. (October 18, 2006) -- ¾ Newly published data from a large, two-year trial published in the November issue of Kidney International report on the effects of chronic kidney disease (CKD ...

UK drugmaker Shire will be disappointed by news that its Fosrenol failed to meet the primary endpoint of a Phase II trial of reducing the amount of phosphate in pre-dialysis patients with stage 3 and ...

Nov. 4, 2002 — Lanthanum carbonate (Fosrenol) is safe and effective for the treatment of hemodialysis patients with hyperphosphatemia, according to two presentations on Nov. 2 at the American Society ...

Shire’s Fosrenol can dramatically reduce the number of tablets that patients with end-stage renal disease need to take to control high blood phosphate levels, according to the results of a ‘real world ...

PHILADELPHIA and BASINGSTOKE, England, November 6 -- Shire plc today announced the results of a Phase II study indicating that FOSRENOL can effectively reduce serum phosphate levels in chronic kidney ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. FOSRENOL contains the active ingredient lanthanum carbonate hydrate.

Lanthum carbonate 750mg, 1000mg; per stick pack. Tabs 500mg patient pack (2 x 45 tabs)—1; Tabs 750mg patient pack (6 x 15 tabs)—1; Tabs 1000mg patient pack (9 x 10 tabs)—1; Oral pwd stick pack—10; ...

Philadelphia, PA - Shire Pharmaceuticals announced November 28, 2005 that the FDA has granted approval for new 750-mg and 1.0-g strengths of the noncalcium phosphate binder lanthanum carbonate ...

Shire has submitted marketing applications in 28 European nations, including Sweden. The national approvals are expected to commence in the second quarter of 2012. Fosrenol is approved for ...

PHILADELPHIA, Pennsylvania and DUBLIN, Ireland, February 9 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), announces that it has received Paragraph IV ...